Literature DB >> 1939059

Phosphorylation of caldesmon by p34cdc2 kinase. Identification of phosphorylation sites.

A S Mak1, M Carpenter, L B Smillie, J H Wang.   

Abstract

It has recently been shown that caldesmon from non-muscle (Yamashiro, S., Yamakita, Y., Hosoya, H., and Matsumura, F. (1991) Nature 349, 169-172) and smooth muscle cells (Mak, A. S., Watson, M. H., Litwin, C. M. E., and Wang, J. H. (1991) J. Biol. Chem. 266, 6678-6681) can be phosphorylated in vitro by p34cdc2 kinase resulting in the inhibition of caldesmon binding to F-actin and Ca(2+)-calmodulin. In this study, we have identified five phosphorylation sites in smooth muscle caldesmon at Ser582, Ser667, Thr673, Thr696, and Ser702. All the sites bear some resemblance to the S(T)-P-X-X motif recognized by p34cdc2. The preferred site of phosphorylation at Thr673 accounts for about 40% of the total phosphorylation. Four of the sites occur in two pairs of closely spaced sites, Ser667/Thr673 and Thr696/Ser702; phosphorylation of one site in each pair inhibits strongly the phosphorylation of the second site in the same pair, presumably due to the close proximity of the two sites. Similar negative cooperativity in phosphorylation of Ser667 and Thr673 was observed using a 22-residue synthetic peptide containing the two sites. Phosphorylation of Ser667/Thr673 and Thr696/Ser702 account for about 90% of the total level of phosphorylation and these sites are located within the 10-kDa CNBr fragment at the COOH-terminal end of caldesmon known to bind actin and Ca(2+)-calmodulin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939059

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Mutant Caldesmon lacking cdc2 phosphorylation sites delays M-phase entry and inhibits cytokinesis.

Authors:  S Yamashiro; H Chern; Y Yamakita; F Matsumura
Journal:  Mol Biol Cell       Date:  2001-01       Impact factor: 4.138

2.  The Levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2'-deoxycytidine therapy.

Authors:  Cynthia C Smith; Baiquan Li; Juan Liu; Kie-Sok Lee; Laure Aurelian
Journal:  Cancer Invest       Date:  2011-07       Impact factor: 2.176

3.  Activation of MAP kinases and phosphorylation of caldesmon in canine colonic smooth muscle.

Authors:  W T Gerthoffer; I A Yamboliev; M Shearer; J Pohl; R Haynes; S Dang; K Sato; J R Sellers
Journal:  J Physiol       Date:  1996-09-15       Impact factor: 5.182

4.  Protein phosphatase 2A1 is the major enzyme in vertebrate cell extracts that dephosphorylates several physiological substrates for cyclin-dependent protein kinases.

Authors:  P Ferrigno; T A Langan; P Cohen
Journal:  Mol Biol Cell       Date:  1993-07       Impact factor: 4.138

5.  Identification of multiple genes in bovine retinal pericytes altered by exposure to elevated levels of glucose by using mRNA differential display.

Authors:  L P Aiello; G S Robinson; Y W Lin; Y Nishio; G L King
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

6.  MEK modulates force-fluctuation-induced relengthening of canine tracheal smooth muscle.

Authors:  M L Dowell; T L Lavoie; O J Lakser; N O Dulin; J J Fredberg; W T Gerthoffer; C Y Seow; R W Mitchell; J Solway
Journal:  Eur Respir J       Date:  2010-01-28       Impact factor: 16.671

7.  Phosphorylation of caldesmon by smooth-muscle casein kinase II.

Authors:  C Sutherland; B S Renaux; D J McKay; M P Walsh
Journal:  J Muscle Res Cell Motil       Date:  1994-08       Impact factor: 2.698

Review 8.  Caldesmon as a therapeutic target for proliferative vascular diseases.

Authors:  Chi-Ming Hai
Journal:  Mini Rev Med Chem       Date:  2008-10       Impact factor: 3.862

9.  Smooth-muscle caldesmon phosphatase is SMP-I, a type 2A protein phosphatase.

Authors:  M D Pato; C Sutherland; S J Winder; M P Walsh
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

Review 10.  Caldesmon and the regulation of cytoskeletal functions.

Authors:  C L Albert Wang
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.